J Med Assoc Thai 2005; 88 (9):1228

Views: 398 | Downloads: 7 | Responses: 0

PDF XML Respond to this article Print Alert & updates Request permissions Email to a friend

Efficacy and Safety of Bimatoprost for the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Three-Month, Open-Label Study in Community-Based Practices in Thailand
Wanichwecha-rungruang B Mail, Iemsomboon W

The authors evaluated the effectiveness and safety of bimatoprost using an open-label, non-comparative, three-month, community-based surveillance study. Patients (n = 458) with open-angle glaucoma or ocular hypertension received bimatoprost 0.03% ophthalmic solution as monotherapy, replacement therapy or adjunctive therapy. Bimatoprost produced a rapid, significant (p < 0.0001) reduction in intraocular pressure: monotherapy (34.6% reduction); replacement therapy (16.4% reduction); adjunctive therapy (24.1% reduction). Bimatoprost enabled more patients to achieve their pre-defined target intraocular pressure (p < 0.0001), compared to previous treatments, and significantly lowered intraocular pressure, regardless of the patients’ baseline pressure level or history of pressure control. Bimatoprost was well-tolerated; the most commonly reported adverse event was conjunctival hyperaemia (19.9%). Most patients and ophthalmologists rated bimatoprost highly, compared to previously used treatments. The authors concluded that bimatoprost is an effective, well-tolerated treatment for lowering intraocular pressure in Thai patients with open-angle
glaucoma or ocular hypertension.

Keywords: Bimatoprost, Open angle glaucoma, Ocular hypertension, Intraocular pressure, Thailand

Download: PDF